Home » FDA Approves Eli Lilly’s Taltz for Nonradiographic Axial Spondyloarthritis
FDA Approves Eli Lilly’s Taltz for Nonradiographic Axial Spondyloarthritis
Eli Lilly’s Taltz (ixekizumab) has received the FDA’s approval for treatment of active nonradiographic axial spondyloarthritis (nr-axSpA) in patients with objective signs of inflammation.
The approval was based on the results of a phase 3 trial, in which 30 percent of patients treated with 80 mg of Taltz every four weeks demonstrated improvement compared to 13 percent of patients treated with a placebo at week 52.
Taltz is the first IL-17A antagonist approved by the FDA for treatment of the disease.
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May